Drugs / Pembroluzimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07513324 | Jul 2026 → Jan 2028 expected | oropharynx squamous cell carcinoma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembroluzimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513324 ↗ |